Wechselwirkungen von Spironolacton

Spironolacton (Aldactone, CaroSpir), ein Aldosteronantagonist, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 340 dokumentierte Wechselwirkungen: 31 schwerwiegende, 257 mittelschwere, 50 geringfügige und 2, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (31)

  • Amiloridkaliumsparendes DiuretikumSchwerwiegend

    Antikaliuretic Therapy or Potassium Supplementation Amiloride HCl should not be given to patients receiving other potassium-conserving agents, such as spironolactone or triamterene. (Fachinformation zu Amilorid, Gegenanzeigen)

  • ArsentrioxidQT-verlängerndes ArzneimittelSchwerwiegend

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (Fachinformation zu Arsentrioxid, Warnhinweise und Vorsichtsmaßnahmen)

  • BumetanidSchleifendiuretikumSchwerwiegend

    WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (Fachinformation zu Bumetanid, Boxed Warning (umrahmter Warnhinweis))

  • CandesartanAngiotensin-II-Rezeptorblocker (Sartan)Schwerwiegend

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (Fachinformation zu Candesartan, Arzneimittelwechselwirkungen)

  • Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (Fachinformation zu Choriogonadotropin alfa, Warnhinweise)

  • CiclosporinImmunsuppressivumSchwerwiegend

    Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (Fachinformation zu Ciclosporin, Arzneimittelwechselwirkungen)

  • ClozapinAntipsychotikumSchwerwiegend

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Fachinformation zu Clozapin, Boxed Warning (umrahmter Warnhinweis))

  • DofetilidAntiarrhythmikumSchwerwiegend

    In the DIAMOND trials, 1252 patients were treated with dofetilide and diuretics concomitantly, of whom 493 died compared to 508 deaths among the 1248 patients receiving placebo and diuretics. (Fachinformation zu Dofetilid, Arzneimittelwechselwirkungen)

  • DroperidolDopaminantagonistSchwerwiegend

    Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (Fachinformation zu Droperidol, Boxed Warning (umrahmter Warnhinweis))

  • EnalaprilACE-HemmerSchwerwiegend

    Avoid potassium sparing agents in patients with heart failure ( 7.3 ). (Fachinformation zu Enalapril, Arzneimittelwechselwirkungen)

  • EnalaprilatACE-HemmerSchwerwiegend

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Fachinformation zu Enalaprilat, Warnhinweise)

  • EplerenonAldosteronantagonistSchwerwiegend

    Spironolactone oral suspension is contraindicated for patients with the following conditions: Hyperkalemia Addison’s disease Concomitant use of eplerenone Spironolactone oral suspension is contraindicated in patients with ( 4 ): Hyperkalemia Addison’s disease Concomitant use of eplerenone (Fachinformation zu Spironolacton, Gegenanzeigen)

  • EptifibatidThrombozytenaggregationshemmerSchwerwiegend

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Fachinformation zu Eptifibatid, Gegenanzeigen)

  • EtacrynsäureSchleifendiuretikumSchwerwiegend

    CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (Fachinformation zu Etacrynsäure, Gegenanzeigen)

  • FollitropinSchwerwiegend

    Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (Fachinformation zu Follitropin, Warnhinweise und Vorsichtsmaßnahmen)

  • GentamicinAminoglykosidSchwerwiegend

    The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Gentamicin, Boxed Warning (umrahmter Warnhinweis))

  • IrinotecanSchwerwiegend

    Avoid diuretics or laxatives in patients with diarrhea. (Fachinformation zu Irinotecan, Warnhinweise und Vorsichtsmaßnahmen)

  • ItraconazolAzol-AntimykotikumSchwerwiegend

    Diuretics Eplerenone Contraindicated during and 2 weeks after TOLSURA treatment. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

  • KaliumVitamine und MineralstoffeSchwerwiegend

    Diese Arzneimittel verringern die Kaliumausscheidung; zusätzliche Kaliumpräparate oder Salzersatzmittel können eine Hyperkaliämie verursachen, die den Herzrhythmus beeinträchtigt. (NIH Office of Dietary Supplements, Potassium)

  • KaliumcitratKaliumpräparatSchwerwiegend

    Such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). (Fachinformation zu Kaliumcitrat, Gegenanzeigen)

  • MetolazonThiaziddiuretikumSchwerwiegend

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Fachinformation zu Metolazon, Warnhinweise)

  • MinoxidilVasodilatatorSchwerwiegend

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Fachinformation zu Minoxidil, Boxed Warning (umrahmter Warnhinweis))

  • MitotanCYP3A4-InduktorSchwerwiegend

    Spironolactone: Avoid concomitant use with LYSODREN. (Fachinformation zu Mitotan, Arzneimittelwechselwirkungen)

  • NatriumhydrogencarbonatAntazidumSchwerwiegend

    Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (Fachinformation zu Natriumhydrogencarbonat, Gegenanzeigen)

  • NeomycinAminoglykosidSchwerwiegend

    The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (Fachinformation zu Neomycin, Boxed Warning (umrahmter Warnhinweis))

  • Nirmatrelvir und RitonavirVirostatikumSchwerwiegend

    …2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor:… (Fachinformation zu Nirmatrelvir und Ritonavir, Gegenanzeigen)

  • QuinaprilACE-HemmerSchwerwiegend

    …sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (Fachinformation zu Quinapril, Warnhinweise)

  • Quinapril und HydrochlorothiazidACE-HemmerSchwerwiegend

    …sometimes associated with oliguria and/or progressive azotemia, and rarely acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis or severe volume and/or salt depletion of any etiology. (Fachinformation zu Quinapril und Hydrochlorothiazid, Warnhinweise)

  • TadalafilPDE-5-HemmerSchwerwiegend

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Fachinformation zu Tadalafil, Warnhinweise und Vorsichtsmaßnahmen)

  • Triamterenkaliumsparendes DiuretikumSchwerwiegend

    Two deaths have been reported in patients receiving concomitant spironolactone and Dyrenium or Dyazide ® . (Fachinformation zu Triamteren, Gegenanzeigen)

  • Triamteren und Hydrochlorothiazidkaliumsparendes DiuretikumSchwerwiegend

    CONTRAINDICATIONS Antikaliuretic Therapy and Potassium Supplementation Triamterene and hydrochlorothiazide should not be given to patients receiving other potassium-sparing agents such as spironolactone, amiloride, or other formulations containing triamterene. (Fachinformation zu Triamteren und Hydrochlorothiazid, Gegenanzeigen)

Mittelschwere Wechselwirkungen (257)

  • AcebutololBetablockerMittelschwer

    Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (Fachinformation zu Acebutolol, Warnhinweise)

  • AcetazolamidCarboanhydrasehemmerMittelschwer

    …drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • AcetylsalicylsäureNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Acetylsalicylsäure und DipyridamolThrombozytenaggregationshemmerMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • AdrenalinSympathomimetikumMittelschwer

    …Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

  • AlfuzosinAlphablockerMittelschwer

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Fachinformation zu Alfuzosin, Warnhinweise und Vorsichtsmaßnahmen)

  • AliskirenAntihypertensivumMittelschwer

    Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, combination use with ARBs or ACEIs [see Contraindications ( 4 ), Warnings and Precautions ( 5.2 ), and Clinical Studies ( 14.3 )] , NSAIDs, or potassium supplements or potassium sparing diuretics. (Fachinformation zu Aliskiren, Warnhinweise und Vorsichtsmaßnahmen)

  • AllopurinolXanthinoxidasehemmerMittelschwer

    Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (Fachinformation zu Allopurinol, Warnhinweise und Vorsichtsmaßnahmen)

  • Alogliptin und MetforminDPP-4-HemmerMittelschwer

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

  • AmfepramonZNS-StimulansMittelschwer

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Fachinformation zu Amfepramon, Arzneimittelwechselwirkungen)

  • AmikacinAminoglykosidMittelschwer

    Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (Fachinformation zu Amikacin, Arzneimittelwechselwirkungen)

  • AmiodaronAntiarrhythmikumMittelschwer

    Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. (Fachinformation zu Amiodaron, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und BenazeprilDihydropyridin-CalciumkanalblockerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • ArformoterolBeta-Adrenozeptor-AgonistMittelschwer

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Fachinformation zu Arformoterol, Arzneimittelwechselwirkungen)

  • AripiprazolAntipsychotikumMittelschwer

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Fachinformation zu Aripiprazol, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansMittelschwer

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Fachinformation zu Armodafinil, Warnhinweise und Vorsichtsmaßnahmen)

  • AsenapinAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Fachinformation zu Asenapin, Warnhinweise und Vorsichtsmaßnahmen)

  • AtenololBetablockerMittelschwer

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Fachinformation zu Atenolol, Warnhinweise)

  • Atenolol und ChlortalidonBetablockerMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • AtomoxetinNoradrenalin-WiederaufnahmehemmerMittelschwer

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Fachinformation zu Atomoxetin, Arzneimittelwechselwirkungen)

  • AvanafilPDE-5-HemmerMittelschwer

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Fachinformation zu Avanafil, Warnhinweise und Vorsichtsmaßnahmen)

  • AzilsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Belladonna und OpiumOpioidMittelschwer

    Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Belladonna und Opium, Arzneimittelwechselwirkungen)

  • BenazeprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Benazepril und HydrochlorothiazidACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • BenzfetaminZNS-StimulansMittelschwer

    Amphetamines may decrease the hypotensive effect of antihypertensives. (Fachinformation zu Benzfetamin, Arzneimittelwechselwirkungen)

  • BexagliflozinSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ) [see Use in Specific Populations ( 8.6 )] , elderly patients, patients with low systolic blood pressure, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Bexagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

  • BisoprololBetablockerMittelschwer

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Fachinformation zu Bisoprolol, Warnhinweise)

  • Bisoprolol und HydrochlorothiazidBetablockerMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • BortezomibMittelschwer

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Fachinformation zu Bortezomib, Warnhinweise und Vorsichtsmaßnahmen)

  • BrexpiprazolAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Brexpiprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • BrimonidinAlpha-Adrenozeptor-AgonistMittelschwer

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

  • Brimonidin und TimololAlpha-Adrenozeptor-AgonistMittelschwer

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

  • BromocriptinDopaminagonistMittelschwer

    Use caution in patients taking antihypertensive medications. (Fachinformation zu Bromocriptin, Warnhinweise und Vorsichtsmaßnahmen)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Fachinformation zu Brompheniramin, Pseudoephedrin und Dextromethorphan, Arzneimittelwechselwirkungen)

  • Budesonid und FormoterolKortikosteroidMittelschwer

    Diuretics: Use with caution. (Fachinformation zu Budesonid und Formoterol, Arzneimittelwechselwirkungen)

  • BuprenorphinOpioidMittelschwer

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Buprenorphin, Arzneimittelwechselwirkungen)

  • Buprenorphin und NaloxonOpioidMittelschwer

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Buprenorphin und Naloxon, Arzneimittelwechselwirkungen)

  • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Butalbital, Paracetamol, Koffein und Codein, Arzneimittelwechselwirkungen)

  • CalciumchloridMittelschwer

    Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (Fachinformation zu Calciumchlorid, Arzneimittelwechselwirkungen)

  • CanagliflozinSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Canagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

  • Candesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • CaptoprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbamazepinAntiepileptikumMittelschwer

    Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (Fachinformation zu Carbamazepin, Warnhinweise und Vorsichtsmaßnahmen)

  • CarbidopaMittelschwer

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Fachinformation zu Carbidopa, Arzneimittelwechselwirkungen)

  • Carbidopa und Levodopadopaminerges ArzneimittelMittelschwer

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Fachinformation zu Carbidopa und Levodopa, Arzneimittelwechselwirkungen)

  • Carbidopa, Levodopa und Entacapondopaminerges ArzneimittelMittelschwer

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Fachinformation zu Carbidopa, Levodopa und Entacapon, Arzneimittelwechselwirkungen)

  • CariprazinAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Cariprazin, Warnhinweise und Vorsichtsmaßnahmen)

  • CarvedilolBetablockerMittelschwer

    If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Fachinformation zu Carvedilol, Warnhinweise und Vorsichtsmaßnahmen)

  • CefepimCephalosporinMittelschwer

    Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (Fachinformation zu Cefepim, Arzneimittelwechselwirkungen)

  • CeftazidimCephalosporinMittelschwer

    Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (Fachinformation zu Ceftazidim, Arzneimittelwechselwirkungen)

  • CelecoxibNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • ChinidinAntiarrhythmikumMittelschwer

    Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (Fachinformation zu Chinidin, Arzneimittelwechselwirkungen)

  • ChlorothiazidThiaziddiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • ChlorpromazinAntipsychotikumMittelschwer

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Fachinformation zu Chlorpromazin, Vorsichtsmaßnahmen)

  • ChlortalidonThiaziddiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • CitalopramSSRIMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Citalopram, Warnhinweise und Vorsichtsmaßnahmen)

  • ClofarabinAntimetabolitMittelschwer

    Consider use of diuretics and/or albumin. (Fachinformation zu Clofarabin, Warnhinweise und Vorsichtsmaßnahmen)

  • CodeinOpioidMittelschwer

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Codein, Arzneimittelwechselwirkungen)

  • ColestyraminGallensäurebinderMittelschwer

    Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Fachinformation zu Colestyramin, Arzneimittelwechselwirkungen)

  • CyclobenzaprinMuskelrelaxansMittelschwer

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Fachinformation zu Cyclobenzaprin, Arzneimittelwechselwirkungen)

  • CyclophosphamidImmunsuppressivumMittelschwer

    …inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone… (Fachinformation zu Cyclophosphamid, Arzneimittelwechselwirkungen)

  • DapagliflozinSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Dapagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

  • Dapagliflozin und MetforminSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Dapagliflozin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

  • Desipramintrizyklisches AntidepressivumMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (Fachinformation zu Desipramin, Warnhinweise)

  • DesmopressinMittelschwer

    …Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (Fachinformation zu Desmopressin, Arzneimittelwechselwirkungen)

  • DesvenlafaxinSNRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (Fachinformation zu Desvenlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

  • DexlansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Fachinformation zu Dexlansoprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • DexmethylphenidatZNS-StimulansMittelschwer

    • Antihypertensive Drugs: Monitor blood pressure. (Fachinformation zu Dexmethylphenidat, Arzneimittelwechselwirkungen)

  • DiazoxidMittelschwer

    The concomitant administration of thiazides or other diuretics may potentiate the hyperglycemic and hyperuricemic effects of PROGLYCEM. (Fachinformation zu Diazoxid, Arzneimittelwechselwirkungen)

  • DiclofenacNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • DiclofenamidCarboanhydrasehemmerMittelschwer

    Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (Fachinformation zu Diclofenamid, Arzneimittelwechselwirkungen)

  • DiflunisalNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • DigoxinDigitalisglykosidMittelschwer

    Digoxin Spironolactone and its metabolites increase the apparent exposure to digoxin. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • DoxercalciferolVitamin-D-AnalogonMittelschwer

    Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Fachinformation zu Doxercalciferol, Warnhinweise und Vorsichtsmaßnahmen)

  • Drospirenon und Ethinylestradiolorales KontrazeptivumMittelschwer

    …[See Adverse Reactions ( 6 ).] Figure 1: VTE Risk with Yasmin Relative to LNG-Containing COCs (adjusted risk#) Figure 2 Likelihood of Developing a VTE 5.2 Hyperkalemia Yaz contains 3 mg of the progestin DRSP which has anti-mineralocorticoid activity, including the potential for hyperkalemia in high-risk patients, comparable to a 25 mg dose of spironolactone. (Fachinformation zu Drospirenon und Ethinylestradiol, Warnhinweise und Vorsichtsmaßnahmen)

  • DuloxetinSNRIMittelschwer

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Fachinformation zu Duloxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • EmpagliflozinSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Empagliflozin, Warnhinweise und Vorsichtsmaßnahmen)

  • Empagliflozin und MetforminSGLT-2-HemmerMittelschwer

    Patients with impaired renal function (eGFR less than 60 mL/min/1.73 m 2 ), elderly patients, or patients on loop diuretics may be at increased risk for volume depletion or hypotension. (Fachinformation zu Empagliflozin und Metformin, Warnhinweise und Vorsichtsmaßnahmen)

  • Enalapril und HydrochlorothiazidACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Examples of drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium… (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Epoetin alfaMittelschwer

    Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Fachinformation zu Epoetin alfa, Warnhinweise und Vorsichtsmaßnahmen)

  • EpoprostenolProstaglandin-AnalogonMittelschwer

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Fachinformation zu Epoprostenol, Arzneimittelwechselwirkungen)

  • EscitalopramSSRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fachinformation zu Escitalopram, Warnhinweise und Vorsichtsmaßnahmen)

  • EsmololBetablockerMittelschwer

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Fachinformation zu Esmolol, Arzneimittelwechselwirkungen)

  • EsomeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Fachinformation zu Esomeprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • EtodolacNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • FampridinKaliumpräparatMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • FenoprofenNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • FentanylOpioidMittelschwer

    …treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (Fachinformation zu Fentanyl, Warnhinweise und Vorsichtsmaßnahmen)

  • FluconazolAzol-AntimykotikumMittelschwer

    An effect of this magnitude should not necessitate a change in the fluconazole dose regimen in subjects receiving concomitant diuretics. (Fachinformation zu Fluconazol, Arzneimittelwechselwirkungen)

  • FludrocortisonKortikosteroidMittelschwer

    Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (Fachinformation zu Fludrocortison, Arzneimittelwechselwirkungen)

  • FluoxetinSSRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • FlurbiprofenNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Fluticason und SalmeterolKortikosteroidMittelschwer

    Diuretics: Use with caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

  • FluvoxaminSSRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (Fachinformation zu Fluvoxamin, Warnhinweise und Vorsichtsmaßnahmen)

  • FormoterolBeta-Adrenozeptor-AgonistMittelschwer

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (Fachinformation zu Formoterol, Arzneimittelwechselwirkungen)

  • FoscarnetVirostatikumMittelschwer

    When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (Fachinformation zu Foscarnet, Arzneimittelwechselwirkungen)

  • FosinoprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Fosinopril und HydrochlorothiazidACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • FurosemidSchleifendiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • GlimepiridSulfonylharnstoffMittelschwer

    …danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

  • GlipizidSulfonylharnstoffMittelschwer

    …may reduce the glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

  • Antihypertensives: Possible additive hypotensive effects. (Fachinformation zu Glyceroltrinitrat (Nitroglycerin), Arzneimittelwechselwirkungen)

  • HaloperidolAntipsychotikumMittelschwer

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (Fachinformation zu Haloperidol, Arzneimittelwechselwirkungen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Examples of drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium… (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • HydrochlorothiazidThiaziddiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • HydrocodonOpioidMittelschwer

    Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Hydrocodon, Arzneimittelwechselwirkungen)

  • Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Fachinformation zu Hydrocodon und Chlorphenamin, Arzneimittelwechselwirkungen)

  • Hydrocodon und HomatropinOpioidMittelschwer

    Diuretics : Hydrocodone may reduce the efficacy of diuretics. (Fachinformation zu Hydrocodon und Homatropin, Arzneimittelwechselwirkungen)

  • Hydrocodon und IbuprofenOpioidMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Hydrocodon und ParacetamolOpioidMittelschwer

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Hydrocodon und Paracetamol, Arzneimittelwechselwirkungen)

  • HydromorphonOpioidMittelschwer

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Hydromorphon, Arzneimittelwechselwirkungen)

  • IbuprofenNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Ibuprofen und FamotidinNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • IloperidonAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Fachinformation zu Iloperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • Imipramintrizyklisches AntidepressivumMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (Fachinformation zu Imipramin, Warnhinweise)

  • IndapamidThiaziddiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • IndometacinNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Insulin aspartInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

  • Insulin degludecInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g.,… (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

  • Insulin detemirInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

  • Insulin glarginInsulinMittelschwer

    Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents… (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

  • Insulin lisproInsulinMittelschwer

    Drugs That May Decrease the Blood Glucose Lowering Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

  • Ipratropiumbromid und SalbutamolAnticholinergikumMittelschwer

    Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (Fachinformation zu Ipratropiumbromid und Salbutamol, Arzneimittelwechselwirkungen)

  • IrbesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Irbesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • KaliumchloridKaliumpräparatMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • KaliumiodidMittelschwer

    Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (Fachinformation zu Kaliumiodid, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Diuretics eplerenone The potential increase in plasma concentrations of eplerenone when coadministered with ketoconazole tablets may increase the risk of hyperkalemia and hypotension. (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

  • KetoprofenNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • KetorolacNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • LansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (Fachinformation zu Lansoprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • LevomilnacipranSNRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (Fachinformation zu Levomilnacipran, Warnhinweise und Vorsichtsmaßnahmen)

  • LevorphanolOpioidMittelschwer

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Levorphanol, Arzneimittelwechselwirkungen)

  • LevosalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Fachinformation zu Levosalbutamol, Arzneimittelwechselwirkungen)

  • LinezolidAntibiotikumMittelschwer

    Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (Fachinformation zu Linezolid, Warnhinweise und Vorsichtsmaßnahmen)

  • LisinoprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Lisinopril und HydrochlorothiazidACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Lithiumserotonerges ArzneimittelMittelschwer

    Lithium: Increased risk of lithium toxicity ( 7.2 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • LosartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Losartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • LovastatinStatinMittelschwer

    Caution should also be exercised if an HMG-CoA reductase inhibitor or other agent used to lower cholesterol levels is administered to patients also receiving other drugs (e.g., spironolactone, cimetidine) that may decrease the levels or activity of endogenous steroid hormones. (Fachinformation zu Lovastatin, Arzneimittelwechselwirkungen)

  • LumateperonAntipsychotikumMittelschwer

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Fachinformation zu Lumateperon, Warnhinweise und Vorsichtsmaßnahmen)

  • LurasidonAntipsychotikumMittelschwer

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Fachinformation zu Lurasidon, Warnhinweise und Vorsichtsmaßnahmen)

  • MecamylaminAntihypertensivumMittelschwer

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (Fachinformation zu Mecamylamin, Arzneimittelwechselwirkungen)

  • MefenaminsäureNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • MeloxicamNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • MethadonOpioidMittelschwer

    Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (Fachinformation zu Methadon, Warnhinweise und Vorsichtsmaßnahmen)

  • MethylphenidatZNS-StimulansMittelschwer

    Antihypertensive Drugs: Monitor blood pressure. (Fachinformation zu Methylphenidat, Arzneimittelwechselwirkungen)

  • MetoprololBetablockerMittelschwer

    If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (Fachinformation zu Metoprolol, Warnhinweise und Vorsichtsmaßnahmen)

  • Metoprolol und HydrochlorothiazidBetablockerMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • MidazolamBenzodiazepinMittelschwer

    Dosage adjustments of the drugs metabolized by CYP2C8 (e.g., repaglinide) and CYP3A4/5 (e.g., midazolam, sirolimus and tacrolimus) may be necessary if they are given concurrently with spironolactone. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • MilnacipranSNRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (Fachinformation zu Milnacipran, Warnhinweise und Vorsichtsmaßnahmen)

  • MirtazapinAntidepressivumMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (Fachinformation zu Mirtazapin, Warnhinweise und Vorsichtsmaßnahmen)

  • ModafinilZNS-StimulansMittelschwer

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Fachinformation zu Modafinil, Warnhinweise und Vorsichtsmaßnahmen)

  • MoexiprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • MorphinOpioidMittelschwer

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Morphin, Arzneimittelwechselwirkungen)

  • NabumetonNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • NadololBetablockerMittelschwer

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Fachinformation zu Nadolol, Warnhinweise)

  • NalbuphinOpioidMittelschwer

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Nalbuphin, Arzneimittelwechselwirkungen)

  • NaproxenNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Naproxen und EsomeprazolNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • NateglinidGlinidMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (Fachinformation zu Natrium-Zirconium-Cyclosilicat, Warnhinweise und Vorsichtsmaßnahmen)

  • NatriumpolystyrolsulfonatKaliumpräparatMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Fachinformation zu Nicotinsäure (Niacin), Arzneimittelwechselwirkungen)

  • NifedipinDihydropyridin-CalciumkanalblockerMittelschwer

    Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (Fachinformation zu Nifedipin, Arzneimittelwechselwirkungen)

  • NimodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Fachinformation zu Nimodipin, Arzneimittelwechselwirkungen)

  • OlanzapinAntipsychotikumMittelschwer

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Fachinformation zu Olanzapin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olanzapin und FluoxetinAntipsychotikumMittelschwer

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Olanzapin und Fluoxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • OliceridinOpioidMittelschwer

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Oliceridin, Arzneimittelwechselwirkungen)

  • OlmesartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • OmeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Fachinformation zu Omeprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • Omeprazol und NatriumhydrogencarbonatProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (Fachinformation zu Omeprazol und Natriumhydrogencarbonat, Warnhinweise und Vorsichtsmaßnahmen)

  • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • OxaprozinNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • OxycodonOpioidMittelschwer

    Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Oxycodon, Arzneimittelwechselwirkungen)

  • Oxycodon und ParacetamolOpioidMittelschwer

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Oxycodon und Paracetamol, Arzneimittelwechselwirkungen)

  • OxymorphonOpioidMittelschwer

    Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Oxymorphon, Arzneimittelwechselwirkungen)

  • PaliperidonAntipsychotikumMittelschwer

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Paliperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • PantoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Fachinformation zu Pantoprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • Paracetamol und CodeinOpioidMittelschwer

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Paracetamol und Codein, Arzneimittelwechselwirkungen)

  • NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • ParicalcitolVitamin-D-AnalogonMittelschwer

    The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (Fachinformation zu Paricalcitol, Warnhinweise und Vorsichtsmaßnahmen)

  • ParoxetinSSRIMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (Fachinformation zu Paroxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • PazopanibMittelschwer

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Fachinformation zu Pazopanib, Warnhinweise und Vorsichtsmaßnahmen)

  • Pentazocin und NaloxonOpioidMittelschwer

    Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Pentazocin und Naloxon, Arzneimittelwechselwirkungen)

  • PentoxifyllinMethylxanthinMittelschwer

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Fachinformation zu Pentoxifyllin, Arzneimittelwechselwirkungen)

  • PerindoprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • PethidinOpioidMittelschwer

    Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Pethidin, Arzneimittelwechselwirkungen)

  • PhenelzinMAO-HemmerMittelschwer

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (Fachinformation zu Phenelzin, Warnhinweise)

  • Phentermin und TopiramatZNS-StimulansMittelschwer

    In addition, when phentermine and topiramate extended-release capsules are used in conjunction with nonpotassium sparing diuretics this may further potentiate potassium-wasting. (Fachinformation zu Phentermin und Topiramat, Warnhinweise und Vorsichtsmaßnahmen)

  • PindololBetablockerMittelschwer

    Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (Fachinformation zu Pindolol, Warnhinweise)

  • Pioglitazon und GlimepiridThiazolidindion (Glitazon)Mittelschwer

    …danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline),… (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

  • PiroxicamNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • PrazosinAlphablockerMittelschwer

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (Fachinformation zu Prazosin, Warnhinweise)

  • ProchlorperazinAntipsychotikumMittelschwer

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Fachinformation zu Prochlorperazin, Vorsichtsmaßnahmen)

  • Promethazin und CodeinOpioidMittelschwer

    Diuretics : Codeine may reduce the efficacy of diuretics. (Fachinformation zu Promethazin und Codein, Arzneimittelwechselwirkungen)

  • QuetiapinAntipsychotikumMittelschwer

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Fachinformation zu Quetiapin, Warnhinweise und Vorsichtsmaßnahmen)

  • RabeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (Fachinformation zu Rabeprazol, Warnhinweise und Vorsichtsmaßnahmen)

  • RamiprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • RepaglinidGlinidMittelschwer

    Dosage adjustments of the drugs metabolized by CYP2C8 (e.g., repaglinide) and CYP3A4/5 (e.g., midazolam, sirolimus and tacrolimus) may be necessary if they are given concurrently with spironolactone. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • RiociguatVasodilatatorMittelschwer

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Fachinformation zu Riociguat, Warnhinweise und Vorsichtsmaßnahmen)

  • RisperidonAntipsychotikumMittelschwer

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Fachinformation zu Risperidon, Warnhinweise und Vorsichtsmaßnahmen)

  • Sacubitril und ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • SalbutamolBeta-Adrenozeptor-AgonistMittelschwer

    Diuretics: Use with caution. (Fachinformation zu Salbutamol, Arzneimittelwechselwirkungen)

  • SalmeterolBeta-Adrenozeptor-AgonistMittelschwer

    • Diuretics: Use with caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

  • SalsalatNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • SertralinSSRIMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Sertralin, Warnhinweise und Vorsichtsmaßnahmen)

  • SildenafilPDE-5-HemmerMittelschwer

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Fachinformation zu Sildenafil, Warnhinweise und Vorsichtsmaßnahmen)

  • SilodosinAlphablockerMittelschwer

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Fachinformation zu Silodosin, Warnhinweise und Vorsichtsmaßnahmen)

  • SirolimusImmunsuppressivumMittelschwer

    Dosage adjustments of the drugs metabolized by CYP2C8 (e.g., repaglinide) and CYP3A4/5 (e.g., midazolam, sirolimus and tacrolimus) may be necessary if they are given concurrently with spironolactone. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • SorafenibMittelschwer

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Fachinformation zu Sorafenib, Warnhinweise und Vorsichtsmaßnahmen)

  • SotalolBetablockerMittelschwer

    Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (Fachinformation zu Sotalol, Warnhinweise und Vorsichtsmaßnahmen)

  • Spironolacton und HydrochlorothiazidAldosteronantagonistMittelschwer

    …drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • …drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • SulindacNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Sumatriptan und NaproxenTriptanMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • SunitinibMittelschwer

    Initiate and/or adjust antihypertensive therapy as appropriate. (Fachinformation zu Sunitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Suxamethoniumneuromuskulärer BlockerMittelschwer

    Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (Fachinformation zu Suxamethonium, Warnhinweise und Vorsichtsmaßnahmen)

  • TacrolimusImmunsuppressivumMittelschwer

    Dosage adjustments of the drugs metabolized by CYP2C8 (e.g., repaglinide) and CYP3A4/5 (e.g., midazolam, sirolimus and tacrolimus) may be necessary if they are given concurrently with spironolactone. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • TapentadolOpioidMittelschwer

    …use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Tapentadol, Arzneimittelwechselwirkungen)

  • TelmisartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Telmisartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • TerazosinAlphablockerMittelschwer

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (Fachinformation zu Terazosin, Warnhinweise und Vorsichtsmaßnahmen)

  • TerbutalinBeta-Adrenozeptor-AgonistMittelschwer

    Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (Fachinformation zu Terbutalin, Vorsichtsmaßnahmen)

  • TestosteronAndrogenMittelschwer

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Fachinformation zu Testosteron, Warnhinweise und Vorsichtsmaßnahmen)

  • TobramycinAminoglykosidMittelschwer

    Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (Fachinformation zu Tobramycin, Arzneimittelwechselwirkungen)

  • TolmetinNSARMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • TolvaptanMittelschwer

    Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (Fachinformation zu Tolvaptan, Warnhinweise und Vorsichtsmaßnahmen)

  • TorasemidSchleifendiuretikumMittelschwer

    NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of spironolactone oral suspension ( 7.3 ) (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Toremifenselektiver Estrogenrezeptormodulator (SERM)Mittelschwer

    Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (Fachinformation zu Toremifen, Arzneimittelwechselwirkungen)

  • TramadolOpioidMittelschwer

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Tramadol, Arzneimittelwechselwirkungen)

  • Tramadol und ParacetamolOpioidMittelschwer

    Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (Fachinformation zu Tramadol und Paracetamol, Arzneimittelwechselwirkungen)

  • TrandolaprilACE-HemmerMittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • TrazodonAntidepressivumMittelschwer

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Fachinformation zu Trazodon, Warnhinweise und Vorsichtsmaßnahmen)

  • TrifluoperazinAntipsychotikumMittelschwer

    Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (Fachinformation zu Trifluoperazin, Vorsichtsmaßnahmen)

  • TrimethoprimAntibiotikumMittelschwer

    …drugs that can increase potassium include: ACE inhibitors angiotensin receptor blockers aldosterone blockers non-steroidal anti-inflammatory drugs (NSAIDs) heparin and low molecular weight heparin trimethoprim 7.2 Lithium Like other diuretics, spironolactone oral suspension reduces the renal clearance of lithium, thus increasing the risk of lithium toxicity. (Fachinformation zu Spironolacton, Arzneimittelwechselwirkungen)

  • Umeclidiniumbromid und VilanterolAnticholinergikumMittelschwer

    • Diuretics: Use with caution. (Fachinformation zu Umeclidiniumbromid und Vilanterol, Arzneimittelwechselwirkungen)

  • ValsartanAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • Valsartan und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    This risk is increased by impaired renal function or concomitant potassium supplementation, potassium-containing salt substitutes or drugs that increase potassium, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [see Drug Interactions ( 7.1 )] . (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • VardenafilPDE-5-HemmerMittelschwer

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Fachinformation zu Vardenafil, Arzneimittelwechselwirkungen)

  • VenlafaxinSNRIMittelschwer

    Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Venlafaxin, Warnhinweise und Vorsichtsmaßnahmen)

  • VerapamilCalciumkanalblockerMittelschwer

    Control patients with milder ventricular dysfunction, if possible, with optimum doses of digitalis and/or diuretics before verapamil treatment is started [see Drug Interactions ( 7.5 )] . (Fachinformation zu Verapamil, Warnhinweise und Vorsichtsmaßnahmen)

  • VilazodonSSRIMittelschwer

    Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (Fachinformation zu Vilazodon, Warnhinweise und Vorsichtsmaßnahmen)

  • VortioxetinAntidepressivumMittelschwer

    Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (Fachinformation zu Vortioxetin, Warnhinweise und Vorsichtsmaßnahmen)

  • ZiprasidonAntipsychotikumMittelschwer

    Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

  • ZoledronsäureBisphosphonatMittelschwer

    Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (Fachinformation zu Zoledronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Geringfügige Erwähnungen (50)

  • AcarboseAntidiabetikumGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

  • AmbrisentanGeringfügig

    Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (Fachinformation zu Ambrisentan, Warnhinweise und Vorsichtsmaßnahmen)

  • Benzylpenicillin (Penicillin G)Penicillin-AntibiotikumGeringfügig

    These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid. (Fachinformation zu Benzylpenicillin (Penicillin G), Arzneimittelwechselwirkungen)

  • BetaxololBetablockerGeringfügig

    In hypertensive patients who have congestive heart failure controlled by digitalis and diuretics, beta-blockers should be administered cautiously. (Fachinformation zu Betaxolol, Warnhinweise)

  • BosentanCYP3A4-InduktorGeringfügig

    Patients required intervention with a diuretic, fluid management, or hospitalization for decompensating heart failure. (Fachinformation zu Bosentan, Warnhinweise und Vorsichtsmaßnahmen)

  • ButorphanolOpioidGeringfügig

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Fachinformation zu Butorphanol, Warnhinweise)

  • CalciumgluconatGeringfügig

    Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (Fachinformation zu Calciumgluconat, Arzneimittelwechselwirkungen)

  • CisplatinGeringfügig

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • CorticotropinGeringfügig

    Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (Fachinformation zu Corticotropin, Arzneimittelwechselwirkungen)

  • DasatinibGeringfügig

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Fachinformation zu Dasatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • Desogestrel und Ethinylestradiolorales KontrazeptivumGeringfügig

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Fachinformation zu Desogestrel und Ethinylestradiol, Warnhinweise)

  • DexamfetaminZNS-StimulansGeringfügig

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Fachinformation zu Dexamfetamin, Arzneimittelwechselwirkungen)

  • DobutaminSympathomimetikumGeringfügig

    Drug Interactions There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen. (Fachinformation zu Dobutamin, Arzneimittelwechselwirkungen)

  • DocetaxelGeringfügig

    Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (Fachinformation zu Docetaxel, Warnhinweise und Vorsichtsmaßnahmen)

  • DronedaronAntiarrhythmikumGeringfügig

    Hypokalemia and Hypomagnesemia with Potassium-Depleting Diuretics Hypokalemia or hypomagnesemia may occur with concomitant administration of potassium-depleting diuretics. (Fachinformation zu Dronedaron, Warnhinweise und Vorsichtsmaßnahmen)

  • EphedrinSympathomimetikumGeringfügig

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Fachinformation zu Ephedrin, Arzneimittelwechselwirkungen)

  • Finasterid5-Alpha-ReduktasehemmerGeringfügig

    …clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (Fachinformation zu Finasterid, Arzneimittelwechselwirkungen)

  • FlecainidAntiarrhythmikumGeringfügig

    Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (Fachinformation zu Flecainid, Arzneimittelwechselwirkungen)

  • GlibenclamidSulfonylharnstoffGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

  • Glibenclamid und MetforminSulfonylharnstoffGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

  • Glipizid und MetforminSulfonylharnstoffGeringfügig

    These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

  • Humaninsulin (Normalinsulin)InsulinGeringfügig

    Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (Fachinformation zu Humaninsulin (Normalinsulin), Arzneimittelwechselwirkungen)

  • HydralazinVasodilatatorGeringfügig

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (Fachinformation zu Hydralazin, Arzneimittelwechselwirkungen)

  • IcatibantGeringfügig

    ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (Fachinformation zu Icatibant, Arzneimittelwechselwirkungen)

  • ImatinibCYP3A4-HemmerGeringfügig

    Weigh patients regularly and manage unexpected rapid weight gain by drug interruption and diuretics. (Fachinformation zu Imatinib, Warnhinweise und Vorsichtsmaßnahmen)

  • IsradipinDihydropyridin-CalciumkanalblockerGeringfügig

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (Fachinformation zu Isradipin, Arzneimittelwechselwirkungen)

  • Linagliptin und MetforminDPP-4-HemmerGeringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

  • MacitentanGeringfügig

    Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (Fachinformation zu Macitentan, Warnhinweise und Vorsichtsmaßnahmen)

  • MetforminBiguanidGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

  • MethyldopaAntihypertensivumGeringfügig

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Fachinformation zu Methyldopa, Arzneimittelwechselwirkungen)

  • MethylprednisolonKortikosteroidGeringfügig

    Amphotericin B injection and potassium-depleting agents : When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Fachinformation zu Methylprednisolon, Arzneimittelwechselwirkungen)

  • MethyltestosteronAndrogenGeringfügig

    In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Methyltestosteron, Warnhinweise)

  • MexiletinAntiarrhythmikumGeringfügig

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Fachinformation zu Mexiletin, Arzneimittelwechselwirkungen)

  • MilrinonPDE-3-HemmerGeringfügig

    …been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (Fachinformation zu Milrinon, Arzneimittelwechselwirkungen)

  • NisoldipinDihydropyridin-CalciumkanalblockerGeringfügig

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (Fachinformation zu Nisoldipin, Arzneimittelwechselwirkungen)

  • NitroprussidnatriumVasodilatatorGeringfügig

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (Fachinformation zu Nitroprussidnatrium, Warnhinweise)

  • Nortriptylintrizyklisches AntidepressivumGeringfügig

    The antihypertensive action of guanethidine and similar agents may be blocked. (Fachinformation zu Nortriptylin, Warnhinweise)

  • Pioglitazon und MetforminThiazolidindion (Glitazon)Geringfügig

    These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

  • Piperacillin und TazobactamPenicillin-AntibiotikumGeringfügig

    Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics. (Fachinformation zu Piperacillin und Tazobactam, Warnhinweise und Vorsichtsmaßnahmen)

  • PlazomicinAminoglykosidGeringfügig

    Worsening of renal function can also occur with concomitant use of nephrotoxic drugs (e.g., aminoglycosides, cisplatin, and NSAIDs). (Fachinformation zu Spironolacton, Warnhinweise und Vorsichtsmaßnahmen)

  • PosaconazolAzol-AntimykotikumGeringfügig

    Management of pseudoaldosteronism may include discontinuation of Noxafil, substitution with an appropriate antifungal drug that is not associated with pseudoaldosteronism, or use of aldosterone receptor antagonists. (Fachinformation zu Posaconazol, Warnhinweise und Vorsichtsmaßnahmen)

  • PrednisolonKortikosteroidGeringfügig

    Potassium-depleting agents (e.g., diuretics, Amphotericin B): When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Fachinformation zu Prednisolon, Arzneimittelwechselwirkungen)

  • PrednisonKortikosteroidGeringfügig

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (Fachinformation zu Prednison, Arzneimittelwechselwirkungen)

  • Protriptylintrizyklisches AntidepressivumGeringfügig

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Fachinformation zu Protriptylin, Warnhinweise)

  • Saxagliptin und MetforminDPP-4-HemmerGeringfügig

    These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

  • Sitagliptin und MetforminDPP-4-HemmerGeringfügig

    Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

  • SulfadiazinSulfonamidGeringfügig

    Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (Fachinformation zu Sulfadiazin, Arzneimittelwechselwirkungen)

  • TerbinafinAntimykotikumGeringfügig

    There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

  • TriamcinolonKortikosteroidGeringfügig

    Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents ( i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. (Fachinformation zu Triamcinolon, Arzneimittelwechselwirkungen)

  • In addition to discontinuation of the drug, diuretic therapy may be required. (Fachinformation zu Veresterte Estrogene und Methyltestosteron, Warnhinweise)

Keine relevante Wechselwirkung berichtet (2)

  • FelodipinDihydropyridin-CalciumkanalblockerKeine Wechselwirkung

    Other Concomitant Therapy - In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with indomethacin or spironolactone. (Fachinformation zu Felodipin, Arzneimittelwechselwirkungen)

  • PamidronsäureBisphosphonatKeine Wechselwirkung

    Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (Fachinformation zu Pamidronsäure, Arzneimittelwechselwirkungen)

Prüfen Sie Spironolacton gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.